Cost-Effectiveness Analysis of First- Through Third-Line Sequential Targeted Therapy in HER2+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cost-Effectiveness Analysis of First- Through Third-Line Sequential Targeted Therapy in HER2+ Metastatic Breast Cancer in the US
Breast Cancer Res Treat 2016 Sep 21;[EPub Ahead of Print], V Diaby, G Adunlin, AA Ali, SB Zeichner, G de Lima Lopes, CG Kohn, AJ MonteroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.